Ultra-Fast Completion in Just Two Years
Establishment of a 120,000-Liter Antibody Drug Facility
Commissioning and Production System Validation to Begin in the Second Half of the Year

Lotte Biologics has established a large-scale contract development and manufacturing organization (CDMO) base in Korea, following its site in Syracuse, New York, thereby building a global dual production system.


On June 22, Lotte Biologics announced that it has completed the major construction of the first plant at the Songdo Bio Campus in Incheon and obtained approval for use. This comes about two years after construction began in 2024.

Lotte Biologics, an aerial view of the 1st plant at Songdo Bio Campus. Lotte Biologics

Lotte Biologics, an aerial view of the 1st plant at Songdo Bio Campus. Lotte Biologics

View original image

The company explained that obtaining this approval for use means not only the completion of site preparation, architecture, and civil engineering, but also the physical establishment of the entire production facility, including manufacturing equipment, piping, and electrical and control systems. Bio manufacturing facilities require high-level design and construction capabilities, as well as systematic quality management, to handle complex cell culture processes and comply with global current Good Manufacturing Practices (cGMP), according to the company.


The first plant is a 120,000-liter-scale antibody drug manufacturing facility, equipped with eight 15,000-liter stainless steel bioreactors to accommodate large-scale commercial production demand. In addition, it incorporates the latest bioprocessing technologies such as high titer cell culture and perfusion, and has introduced an automated logistics warehouse and an operations system based on real-time monitoring to enhance production stability and operational efficiency.


Lotte Biologics stated that it incorporated the operational experience and manufacturing know-how from its Syracuse Bio Campus in New York throughout the construction process of the Songdo first plant. From the design stage, the company established an automated Manufacturing Control System (MCS) to improve production efficiency and quality competitiveness, and designed the facility to maximize its ability to respond to customized customer needs in future commercial production, according to the company.


With the “Dual Site” strategy connecting the Syracuse Bio Campus in the United States and the Songdo site, the company can now provide integrated CDMO services seamlessly linking early clinical to large-scale commercial production. The Syracuse Bio Campus supports global clients’ initial projects and clinical volumes, while the Songdo First Plant is responsible for large-scale commercial manufacturing, thus establishing a dual system. The company explained that this enables a wide range of support from small-scale projects to large commercial volumes. Lotte Biologics also expects that its production network spanning the United States and Korea will enable flexible responses to clients’ regional supply strategies and needs for supply chain risk diversification.


Lotte Biologics plans to begin full-scale commissioning and validation procedures for its production system in the second half of this year. Through this, the company aims to swiftly establish a GMP manufacturing system capable of responding to the commercial production needs of global clients and build a stable commercial production foundation. In addition, Lotte Biologics will continue to enhance production efficiency and quality competitiveness through data-driven process management and the advancement of its digital systems.



James Park, CEO of Lotte Biologics, said, “Completing the major construction and obtaining approval for use of the Songdo First Plant in about two years since breaking ground is the result of our employees’ capabilities and project execution skills, combined with the strategic support and collaboration at the Lotte Group level.” He added, “We will establish ourselves as a trusted CDMO partner for our customers based on a global manufacturing platform connecting Syracuse and Songdo. By proactively responding to the diverse development and commercialization needs of global clients with an integrated production system that ensures speed, quality, and manufacturing flexibility, we will grow into a world-class CDMO company.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing